Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia
Stock Information for Larimar Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.